Marc Hertz
President & Chief Executive Officer GRI Bio, Inc.
Dr. Hertz is a biotechnology executive and entrepreneur with 25+ years of experience leading public and private life sciences companies. He is Co-Founder, President, and CEO of GRI Bio, Inc. (NASDAQ: GRI), and has previously served as CEO of Pharmexa, Inc., the U.S. subsidiary of a publicly traded European biotech, and co-founded multiple biotechnology companies across disease areas. Dr. Hertz has deep scientific expertise in immunology, autoimmunity, fibrosis, and oncology, with a track record of advancing novel therapeutics — including biologics, DNA-based therapies, and small molecules — from concept through Phase 3. He holds a B.A. from Bowdoin College and a Ph.D. in Immunology and Microbiology from the University of Colorado Medical School.
Seminars
- What early clinical and molecular signals tell us about targeting upstream immune pathways, including how gene expression, serum biomarkers, and immune modulation can demonstrate impact on core drivers of fibrosis such as myofibroblast activation, ECM deposition, and epithelial injury
- Evaluating evidence for fibrosis resolution and lung repair, including signals of basement membrane restoration and epithelial cell transition, and how these reshape expectations for what ‘efficacy’ looks like in IPF trials
- Positioning novel therapies in an evolving treatment landscape, including where immune-modulating and regenerative approaches may sit alongside existing antifibrotics, and what differentiation is required to support combination strategies and future standard-of-care integration
